PMID- 15103544
OWN - NLM
STAT- MEDLINE
DCOM- 20041209
LR  - 20151119
IS  - 0940-5429 (Print)
IS  - 0940-5429 (Linking)
VI  - 41 Suppl 1
DP  - 2004 Mar
TI  - New strategies in anaemia management: ACORD (Anaemia CORrection in Diabetes) 
      trial.
PG  - S18-22
AB  - Anaemia is a key component of diabetic nephropathy, but its importance has only 
      recently been recognised. Recombinant human erythropoietin (epoetin) is an 
      established treatment for renal anaemia, and may help to reduce complications 
      associated with diabetic nephropathy, such as cardiovascular disease. The limited 
      experience with the use of epoetin in this patient group prompts the urgent need 
      for clinical data on anaemia correction in early diabetic nephropathy, 
      particularly with regard to benefits on cardiovascular risk reduction. The 
      Anaemia CORrection in Diabetes (ACORD) study will investigate the effects of 
      anaemia correction on cardiac structure and function in patients with early 
      diabetic nephropathy. This 15-month multicentre study will recruit 160 adult 
      patients with diabetes, mild or moderate chronic kidney disease (with creatinine 
      clearance >or=30 ml/min at screening) and moderate anaemia (haemoglobin [Hb], 
      10.5-13.0 g/dl). Patients will be randomised to one of two groups: the early 
      treatment group will receive subcutaneous epoetin beta (NeoRecormon) at study 
      entry to maintain target Hb levels of 13-15 g/dl, while the control group will 
      reflect current practice and will not receive epoetin therapy until Hb levels 
      decline below 10.5 g/dl. The primary efficacy variable, change in left 
      ventricular mass index, will be evaluated at 15 months following randomisation; 
      secondary efficacy variables will include changes in cardiac structure and 
      function over the study period. The ACORD study should provide valuable 
      information on the benefits of anaemia correction in patients with early diabetic 
      nephropathy. The study will also increase awareness of the importance of treating 
      anaemia associated with diabetes.
FAU - Laville, M
AU  - Laville M
AD  - Department of Nephrology, Edouard Herriot Hospital, 5 Place d'Arsonval, F-69437, 
      Lyon Cedex 03, France.
CN  - Anaemia CORrection in Diabetes trial
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
RN  - 0 (Hematinics)
RN  - 0 (Recombinant Proteins)
RN  - 11096-26-7 (Erythropoietin)
RN  - 64FS3BFH5W (Epoetin Alfa)
SB  - IM
MH  - Anemia/*drug therapy/etiology
MH  - Clinical Trials as Topic
MH  - Diabetic Nephropathies/complications/*drug therapy/mortality
MH  - Epoetin Alfa
MH  - Erythropoietin/*therapeutic use
MH  - Hematinics/therapeutic use
MH  - Humans
MH  - Kidney Failure, Chronic/complications/mortality
MH  - Randomized Controlled Trials as Topic
MH  - Recombinant Proteins
MH  - Survival Analysis
MH  - Time Factors
EDAT- 2004/04/23 05:00
MHDA- 2004/12/16 09:00
CRDT- 2004/04/23 05:00
PHST- 2004/04/23 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/04/23 05:00 [entrez]
AID - 10.1007/s00592-004-0134-2 [doi]
PST - ppublish
SO  - Acta Diabetol. 2004 Mar;41 Suppl 1:S18-22. doi: 10.1007/s00592-004-0134-2.